Trial · NCT07049172
Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
NCT07049172, Not applicable, Completed, Wuhan Children's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome. Trials, record NCT07049172. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07049172
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
- NCT number
- NCT07049172
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 91 participants, actual
- Lead sponsor
- Wuhan Children's Hospital
- Conditions
- Nephrotic Syndrome in Children
- Interventions
- Rituximab, Targeted Nursing Care, Baseline Glucocorticoid Therapy, Tacrolimus
- First posted
- 2025-07-03
- Last updated
- 2025-10-01
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Effective Rate | At 6 months post-treatment initiation. | The percentage of participants who achieved a "Significantly effective" or "Effective" response. Efficacy is defined based on remission status, renal function, and proteinuria levels. Total effective rate is calculated as the number of (Significantly effective + Effective) cases divided by the total number of cases in the group. |
| Primary | Recurrence Rate | Within the 6-month follow-up period after treatment initiation. | Relapse defined as urinary protein ≥2+ or urinary protein quantity \>50 mg/kg (or urine protein/creatinine ratio \>2.0 mg/mg), occurring on three consecutive days within a 7-day period, after having achieved remission. |
| Secondary | Change in Quality of Life as Assessed by the Children's Subjective Quality of Life Questionnaire (IS-LQ) | Baseline and at 6 months post-treatment initiation. | The IS-LQ consists of 60 items, scored from 1 to 4, with higher scores indicating better quality of life. Assesses six areas including cognitive, emotional, and overall functioning. |
| Secondary | Adverse Reactions | During the 6-month study period. | Any adverse reactions recorded, including infections, infusion reactions (for rituximab), hypertension, hyperglycemia, electrolyte disturbances, and gastrointestinal symptoms. |
| Other | Peripheral Blood CD19+ B-Cell Count | Monitored monthly in the study group during the 6-month follow-up. | Absolute count of peripheral blood CD19+ B-cells, measured to confirm biological effect of rituximab (B-cell depletion, defined as CD19+ count \<5 cells/μL or \<1% of total lymphocytes). This measure applies to the Rituximab group only. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40993587 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07049172
GET https://conductscience.org/api/trials/v1/NCT07049172/registered